Deutsche Bank AG Raises Stake in Agenus (AGEN)

Deutsche Bank AG lifted its position in Agenus (NASDAQ:AGEN) by 80.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 172,063 shares of the biotechnology company’s stock after acquiring an additional 76,480 shares during the quarter. Deutsche Bank AG’s holdings in Agenus were worth $559,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. RTW Investments LP grew its position in shares of Agenus by 2.6% in the 4th quarter. RTW Investments LP now owns 4,329,816 shares of the biotechnology company’s stock worth $14,115,000 after acquiring an additional 111,296 shares in the last quarter. Hudson Bay Capital Management LP grew its position in shares of Agenus by 60.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock worth $1,467,000 after acquiring an additional 170,000 shares in the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of Agenus in the 4th quarter worth approximately $320,000. BlackRock Inc. grew its position in shares of Agenus by 1.2% in the 4th quarter. BlackRock Inc. now owns 4,883,221 shares of the biotechnology company’s stock worth $15,920,000 after acquiring an additional 55,759 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. grew its position in shares of Agenus by 6.0% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 655,000 shares of the biotechnology company’s stock worth $2,135,000 after acquiring an additional 37,300 shares in the last quarter. Institutional investors own 35.94% of the company’s stock.

Several research analysts have recently commented on the company. Zacks Investment Research lowered Agenus from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. BidaskClub upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, ValuEngine upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

Shares of Agenus opened at $3.35 on Tuesday, according to MarketBeat. The company has a debt-to-equity ratio of -0.11, a quick ratio of 2.16 and a current ratio of 2.16. Agenus has a 52 week low of $3.18 and a 52 week high of $3.51.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, May 7th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). equities research analysts anticipate that Agenus will post -1.52 EPS for the current year.

Agenus Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply